| Prev Close | 142.00 |
| Open | 141.34 |
| Day Low/High | 140.33 / 142.65 |
| 52 Wk Low/High | 101.36 / 147.87 |
| Volume | 2.90M |
| Avg Volume | 3.33M |
Eli Lilly & Co. (LLY)
142.04
0.04
0.03
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 960.13M |
| Market Cap | 135.22B |
| P/E Ratio | 15.86 |
| Div & Yield | 2.96 (1.83%) |
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
All-Time Highs
It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...
Biotech's Big Week Finds a Big Winner in Adaptimmune
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
3 Powerhouse Pharma Stock Favorites
These healthcare stalwarts look attractive for growth and income.
Eli Lilly Has the Base to Support a New Rally
Shares of the pharmaceutical company received a quant upgrade Monday.
Jim Cramer: Nothing's Changed, Except the Prices
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Jim Cramer: The Soundness of My Methods
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Jim Cramer: How to Survive This Violent Rotation
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet
With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
IPO Gives Chinese Couple a 'Hansoh' Sum
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish
Let's step back and look at the bigger picture through charts and indicators.
Jim Cramer: A Tale of Two Stocks
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
Thor Industries and Eli Lilly Offer a Tale of Two Stocks
The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Jim Cramer: Diversification Is Good for Offense, Not Just Defense
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
Jim Cramer: Want a Snapshot of the Economy? Look at the Rails
When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Activists Aim to Eliminate Dual Role for Allergan CEO Saunders
David Tepper's Appaloosa LP renews calls for changes at the top.
